Trending Now
Commercial

Litigation Funding in Brazil Could Explode After 231,000 Patents Are Granted to Reduce Backlog

January 15, 2018

Litigation Funding in Brazil Could Explode After 231,000 Patents Are Granted to Reduce Backlog

For the past 15 years, Brazil has suffered one of the world’s most chronic and severe backlogs of pending patents. Now, the Brazilian Patent and Trademark Office (PTO), is looking to reduce that backlog in one fell swoop: by granting patent rights until 2020 to 231,000 pending applications with no examination. The Brazilian government is seeking to introduce this emergency measure as an “extraordinary solution” to the crisis that has plagued the nation’s patent market for a generation. Brazil’s patent problems arose after it enacted the Patent Statute in 1996, making the nation TRIPS compliant and expanding its range of patentable products and industries. As a result, the number of patent filings has increased 200% over the last 15 years, without a corresponding increase in PTO examiners. Brazil’s current average waiting time for all technological patents is over 10 years. For pharmaceutical and telecom patents, the average wait time is over 13 years. According to the PTO, the current number of examiners (326) is sufficient to handle the present influx of new filings, however it is the backlog that is keeping the PTO in check. Therefore, the PTO has floated the idea that 231,000 pending patents within the backlog (not including pharma patents, which are covered by a separate regulatory body) be immediately granted with no examination required. Here’s where things get tricky, however: a third party would maintain the right to file a pre-grant opposition within 90 days of the automatic patent filing. Should a pre-grant filing take place, the patent application would automatically be reviewed by the PTO. Companies could then theoretically check the automatic patent application list for competitor patents, and file a pre-grant opposition in order to remove their competitors’ patents from the queue. Of course, that type of action would require an upfront legal spend. Perhaps this is an area that astute litigation funders in the market could pursue– There is additional concern, of course, that patents granted via the automatic waiver may in the long run be vulnerable to invalidity challenges in post-grant opposition, as well as the Federal Courts. Local and state judges may also be reluctant to enforce patent decisions in cases involving patents obtained through automatic application. The PTO itself is not beyond judicial reproach; there have already been numerous lawsuits against the PTO grounded on the unlawfulness of the lengthy backlog, which have successfully compelled the PTO to examine a patent application by means of a court order. So it’s not a given that the PTO’s automatic grant will be accepted by state and even federal courts. Again, these are all nitty-gritty details that could play out in the litigation finance industry’s favor, should the PTO move ahead with its suggested ‘extraordinary solution.’

Commercial

View All
Commercial

UK’s Global Rivals Capitalize as PACCAR Funding Reform Stalls

By John Freund |

The United Kingdom's long-promised overhaul of litigation funding regulation has stalled again, and rival jurisdictions are moving to capture the investment that uncertainty is pushing offshore. Nearly three years after the Supreme Court's 2023 decision in *PACCAR* rendered most litigation funding agreements unenforceable by treating them as damages-based agreements, the government has yet to deliver the corrective legislation it pledged.

As reported by The Times, the continued delay is undermining the competitiveness of England and Wales as a global hub for commercial litigation and arbitration. The Ministry of Justice announced in December 2025 that it intended to clarify that litigation funding agreements are not damages-based agreements, with legislation to follow "when parliamentary time allows." But the 2026 King's Speech omitted any litigation funding bill from the legislative programme, leaving funders and claimants without the statutory certainty they had been promised.

Industry participants have voiced deep disappointment, warning that the absence of reform creates an opening for offshore centers that have already implemented clearer rules on funder involvement. While those jurisdictions compete for capital, the UK continues to develop its framework largely through case law, with little appetite for comprehensive statutory change.

The practical effect, observers note, is that funders weighing where to deploy capital may increasingly look beyond London. For a market that has long marketed itself as the world's premier venue for high-value disputes, the prolonged *PACCAR* limbo carries real economic stakes.

Commercial

New York Ruling Opens Litigation Funding to Discovery in Fraud-Tainted Injury Suits

By John Freund |

A New York appellate ruling, paired with the state's newly enacted consumer litigation funding law, is giving defendants fresh tools to scrutinize the financing behind personal-injury claims they suspect are fraudulent. Together, the developments mark a notable shift toward transparency in a market that has historically operated outside the view of courts and opposing parties.

As reported by Law360, the Appellate Division, First Department, held in *Lituma v. Liberty Coca-Cola Beverages LLC* that defendants may obtain discovery into a plaintiff's third-party litigation funding where they present evidence suggesting the underlying claims arose from systemic fraud. The November 2025 decision was the first time the court affirmed an order compelling a personal-injury plaintiff to produce funding-related discovery, vacating the note of issue to allow further inquiry.

The ruling lands alongside New York's Consumer Litigation Funding Act, signed by Governor Kathy Hochul on December 19, 2025, and effective 180 days later. The law caps a funder's recovery at 25% of a case's gross proceeds, requires plain disclosure of all charges and cumulative repayment amounts, and gives consumers a 10-business-day right to cancel without penalty. Attorneys are barred from accepting referral fees or holding financial interests in funding companies.

Notably, the statute stops short of mandating disclosure of funding arrangements during active litigation. For now, defendants seeking to expose questionable financing must rely on rulings like *Lituma* to pry those agreements into the open.

Commercial

Burford Capital Asks Supreme Court to Reverse Third Circuit Arbitration Ruling

By John Freund |

Burford Capital has urged the U.S. Supreme Court to overturn a Third Circuit decision that dismissed, on jurisdictional grounds, the litigation funder's bid to arbitrate a dispute tied to German antitrust litigation. Burford contends the appeals court committed what it called a "fundamental error" in concluding that federal courts lacked authority over the matter.

As reported by Law360, Burford told the justices on June 16 that the Court's own decision earlier this year in Jules v. Andre Balazs Properties is reason enough to undo the Third Circuit's ruling. In Jules, the Court held that a federal court which compels arbitration of federal claims under Section 4 of the Federal Arbitration Act retains subject-matter jurisdiction to confirm or vacate the resulting award, even without an independent basis for federal jurisdiction over the post-award proceeding.

Burford argues that principle squarely governs its case, and that the appeals court's contrary conclusion cannot stand in light of the new precedent. The funder is asking the justices to take up the matter and correct what it describes as a clear jurisdictional misstep.

The stakes extend beyond a single dispute. For funders, the ability to confirm and enforce arbitral awards in federal court is central to monetizing cross-border claims, and a jurisdictional dead-end at the enforcement stage raises both cost and risk. A decision to hear the case could bring welcome clarity for funders pursuing international, arbitration-related recoveries.